AVN's Abreva Herpes Cream To Hit Stores -- Stock Picks

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 03:36:39 10/06/00 Fri
Author: AVN's Abreva Herpes Cream To Hit Stores
Subject: AVN's Abreva Herpes Cream To Hit Stores

AVN's Abreva Herpes Cream To Hit Stores

Herpes Sufferers nationwide anxiously await the arrival of AVN's Abreva Herpes Cream.
Join the hunt along with ZZ and the unknown Herpes sore sufferer as they try top spot AVN's Abreva on a store shelf near you.
At $228.43 per ounze ($15.99 per 2 gm tube retail), the herpes goo stands to make Avanir Pharmacuticals (AVN) a fortune. The company recently signed a distribution deal with SmithKline Beecham giving them a higer than industry standard royalty on the first FDA approved OTC herpes cream. The stock has consistently been reaching new 52 week highs. According to DOWJONES NEWSWIRES on Friday, AVN's "chief executive said
investors are anticipating the launch of its cold sore treatment.
Avanir's Chief Executive Gerald Yakatan said drug store chains are reserving
shelf space for the launch of Avanir's topical cold sore treatment, Abreva,
which will be distributed by Smithkline Beecham PLC (SBH)."

Join the AVN fun and try to spot the herpes goo at a store near you!
http://www.geocities.com/seattlezz/index.html

Other important things to remember about AVN:

$8 to $400 in 17 months!

ABGX did it and there's no reason AVN can't do even better. Once the 4Ps set in! Product, Profits, Partnerships, Phase3/Genital Herpes! Remember the 4Ps because it could give AVN the edge over ABGX! This is what could happen!

http://chart.yahoo.com/t?a=10&b=12&c=98&d=03&e=09&f=00&g=w&s=abgx&y=0&z=abgx

& $8 to $200 in 5 months!

MEDX did it and there's no reason AVN can't do even better.

http://chart.yahoo.com/t?a=09&b=28&c=99&d=03&e=03&f=00&g=w&s=medx&y=0&z=medx

THE 4Ps...Product ( AVN already has an FDA approved Herpes Cream Product), Profits ( AVN already indicates it's coming), Partnerships (AVN already indicates that their Xenerex is already in dicussions), Phase 3/genital herpes (web site already indicates it's coming).

Both ABGX and MEDX became high flying stocks based largely upon their mouse technology. AVN is ready to compete.

"Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human
antibodies faster and cheaper than its
competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody
Technology plc, Hansen said. "

Gregory Hanson, President of AVN's Xenerex
Bioworld Online,
Aug 21, 2000

http://biz.yahoo.com/p/a/avn.html

http://www.avanir.com/

http://www.angelfire.com/wy/moabs/

[ Next Thread | Previous Thread | Next Message | Previous Message ]